The Patented Medicine Prices Review Board (PMPRB) has released its 4th edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2016/17. The report was prepared as part of the National Prescription Drug Utilization Information System (NPDUIS), and examines public drug plan expenditures in Canada, including analyzing the main factors that drive annual changes in prescription drug expenditures.
PMPRB has also released the 2017 Supplement to the Market Intelligence Report, Biologic Response Modifier Agents, 2015, both produced under the NPDUIS initiative. Using data from 2017, the Supplement provides updated information for market trends analyzed in the original report, which focuses on certain biologics that the report refers to as “biologic disease-modifying antirheumatic drugs or biologic DMARDs.”
Lastly, the PMPRB has released its 2017 Annual Report. The 2017 Annual Report includes a review of the PMPRB’s regulatory activities, analyses of sales and price trends of pharmaceuticals, as well as an overview of NPDUIS and analysis of research and development expenditures. On August 22, 2018, the Minister of Health tabled the 2017 Annual Report with the Clerks of the House of Commons and the Senate.
Related Publications & Articles
-
New PMPRB Guidelines will not be implemented January 1, 2023
The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the Board on August 18, 2022 w...Read More -
Ontario is the latest jurisdiction to implement a biosimilars transition policy
On December 20, 2022, Ontario announced it is implementing a biosimilars transition policy. Starting March 31, 2023, patients receiving coverage from the Ontario Drug Benefit plan for the following in...Read More -
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
Pharmaceutical manufacturers in Canada often enter into Product Listing Agreements (PLA), particularly with public payors, to facilitate their drug being reimbursed. It is common for PLAs to take the ...Read More